KSM-66 vs Sensoril vs Shoden: Which Ashwagandha Extract Does the Research Support?

Ashwagandha (Withania somnifera) is one of the most clinically studied adaptogenic herbs in the world — but the majority of that research has not been conducted on generic ashwagandha powder. It has been conducted on specific standardised proprietary extracts with defined and verified withanolide concentrations. Buying a generic ashwagandha supplement without understanding which extract it uses — and at what standardisation — is like buying "fish oil" without knowing how much EPA and DHA it actually contains.

Three proprietary extracts account for the vast majority of published clinical trial evidence: KSM-66, Sensoril, and Shoden. Each has distinct characteristics, dosing ranges, and evidence profiles that make them more or less suitable for different applications.

Why Standardisation Matters: Withanolides Explained

The primary bioactive compounds in ashwagandha are withanolides — steroidal lactones unique to the Withania genus. They are responsible for the adaptogenic, anti-inflammatory, neuroprotective, and anabolic effects documented in clinical research. However, withanolides are a family of over 300 distinct compounds, and different extraction methods and plant parts yield dramatically different withanolide profiles and concentrations.

Standard ashwagandha root powder contains approximately 0.1–0.3% withanolides. Clinical extracts are standardised to 2.5–35% withanolides — an enormous difference in pharmacological potency. This is why clinical trial results on standardised extracts cannot be assumed to apply to low-grade root powder products.

KSM-66: The Most Extensively Studied Extract

KSM-66 (produced by Ixoreal Biomed) is a full-spectrum root-only extract standardised to a minimum of 5% withanolides, produced without alcohol or synthetic solvents using a green chemistry process. It is the most widely studied ashwagandha extract in clinical trials, with over 24 published RCTs covering stress, anxiety, sleep, cognitive function, testosterone, fertility, thyroid function, and athletic performance.

Key KSM-66 clinical highlights:

• The landmark Chandrasekhar 2012 RCT (64 adults, 300mg twice daily for 60 days) — the most-cited ashwagandha stress trial — found 27.9% reduction in serum cortisol and significant stress and anxiety score improvements vs placebo
• A 12-month prospective safety study (Salve et al., 2025, Phytotherapy Research) of 191 adults found KSM-66 at 600mg/day for a full year produced no deleterious effects on hepatic, renal, or thyroid function, with significantly improved quality of life scores and testosterone increases — confirming long-term safety
• VO2max improvement in athletic adults over 8 and 12 weeks with significant quality-of-life improvements across all four WHO-QOL domains
• Sleep: 600mg/day for 8 weeks improved sleep onset latency, total sleep time, sleep efficiency, and mental alertness on waking in a double-blind RCT

Best for: General stress and anxiety reduction, cortisol management, sleep quality, athletic performance, testosterone support. The evidence breadth is unmatched by any other extract. Standard dose: 300–600mg/day.

Sensoril: The Calming, Lower-Dose Option

Sensoril (produced by Natreon) is derived from both the root and leaf of ashwagandha, standardised to 10% withanolides and 32% oligosaccharides. Because it uses the leaf — which contains different withanolide species than the root — its pharmacological profile differs from KSM-66. Sensoril has more pronounced calming and sedating effects, making it better suited to evening use and sleep-focused applications.

The effective clinical dose for Sensoril is 125–250mg/day — significantly lower than KSM-66, reflecting its higher withanolide concentration. Multiple RCTs have confirmed Sensoril's efficacy for stress, anxiety, and sleep at these lower doses. It is also associated with reductions in C-reactive protein (CRP) and cardiovascular risk markers in some trials.

Best for: Anxiety, sleep quality, evening calming use, and those sensitive to higher doses. Lower dose makes it cost-effective per capsule. Standard dose: 125–250mg/day.

Shoden: Highest Withanolide Concentration, Remarkable Cortisol Data

Shoden (produced by Arjuna Natural) is a root and leaf extract standardised to an exceptional 35% withanolide glycosides — the highest concentration of any commercial ashwagandha extract. This means Shoden is effective at extremely low doses (60–120mg/day) that would be impractical with other extracts.

A landmark 2024 double-blind RCT (Heliyon, August 2024) of 60 adults with clinically elevated stress and anxiety (HAMA score >20, morning cortisol >25 mcg/dL) found:

• Morning serum cortisol decreased by 66–67% in both Shoden dose groups vs only 2.2% in placebo (p<0.0001)
• Hamilton Anxiety Rating Scale (HAMA) scores decreased by 59% in both dose groups vs negligible change in placebo (p<0.0001)
• Perceived Stress Scale (PSS) scores decreased by 53–62%
• Testosterone levels increased by 22% (60mg group) and 33% (120mg group) in males vs 4% in placebo (p<0.0001)

These are among the most dramatic cortisol and anxiety reductions reported in any ashwagandha RCT — achieved at doses of just 60–120mg/day due to the high withanolide concentration.

Best for: Clinically elevated cortisol and anxiety, situations where capsule count or dose size matters, and users wanting verified high-potency standardisation. Standard dose: 60–120mg/day.

How to Read Supplement Labels

• Always look for the extract name (KSM-66, Sensoril, or Shoden) explicitly stated on the label — if it is not stated, the withanolide content and extraction method are unverified
• Check the withanolide percentage: KSM-66 ≥5%, Sensoril ≥10%, Shoden ≥35%
• Root-only vs root-and-leaf: KSM-66 is root-only; Sensoril and Shoden use both — different withanolide species, different effect profiles
• Third-party certification (NSF, USP, Informed Sport) verifies that what is on the label is actually in the product